Number of pages: 100-120 | Report Format: PDF | Published date: 27 July, 2022
Historical Years – 2018 & 2019 | Base Year – 2020 | Forecasted Years – 2021 to 2031
The global acquired hemophilia treatment market was pegged at ~US$ 11 billion in 2021 and is expected to witness a CAGR of ~5.06% during the forecast period from 2022 to 2030.
Acquired hemophilia is an autoimmune disease in which the immune system attacks blood clotting factors or disables blood-clotting protein (fibrinogen), leading to excessive bleeding, thus increasing the risk of life-threatening events. Acquired hemophilia can be treated or managed using various treatments and therapies. There are a few methods that are adopted for the treatment such as plasma-derived therapy, recombinant therapy, desmopressin, antifibrinolytic agents, and many more.
The global acquired hemophilia treatment market is showing constant growth. The growing patient base for acquired hemophilia in the world is driving the market. Also, the increasing rate of diagnosis and growing demand for prophylactic treatments are also fueling the market growth. Additionally, the rising awareness among the population and the initiatives taken by various government & private industries or organizations also contribute to the growth of acquired hemophilia treatment market globally.
The global acquired hemophilia treatment market has been analyzed from five perspectives: By Type, Therapy, Treatment, End-User, and Region.
Acquired Hemophilia Treatment Market by Type
Based on type, the global acquired hemophilia treatment market has been segmented into hemophilia A, B, and C. Hemophilia occurs due to the deficiency of the coagulation factors or a particular issue in the proteins that are responsible for the clotting or coagulation procedure in the patient. The common type of hemophilia found in the patients is hemophilia A. Thus, hemophilia A holds the largest share in the market and is expected to continue its dominance in the global market. Hemophilia A occurs when there is a deficiency of the clotting protein i.e., VIII factor. Additionally, hemophilia B holds the second-largest share in the global acquired hemophilia treatment market. The deficiency of factor IX is the root cause of hemophilia B.
Acquired Hemophilia Treatment Market by Therapy
Different types of therapies are used by medical professionals for the treatment of acquired hemophilia, namely gene therapy, immune tolerance induction therapy, replacement therapy, and others. The replacement therapy holds the largest revenue share in the global acquired hemophilia treatment market. Replacement therapy has robust clinical evidence in terms of efficacy since it replaces the missing coagulation factor in the patient. Additionally, gene therapy is the fastest growing segment in the global acquired hemophilia treatment market.
Acquired Hemophilia Treatment Market by Treatment
Based on treatment types, the global acquired hemophilia treatment market has been segmented into on-demand and prophylaxis modes. Prophylaxis is expected to lead the segment with the largest share in the market and is expected to show steady growth in the global market. Prophylaxis is a standard treatment for factor VIII deficiency in patients. prophylactic treatment primarily addresses prevention of abnormal bleeding and reduces hemophilic disability & arthropathy and it also minimizes the need for orthopedic surgery.
Acquired Hemophilia Treatment Market by End User
Based on end-user, the global acquired hemophilia treatment market has been segmented into hospitals and clinics. The hospitals segment is expected to show constant dominance in the acquired hemophilia treatment market with the largest revenue share in the forecast period. Furthermore, this segment also aids to bridge the gap between patients and healthcare services. Hospitals serve as the standard approach for the patients as it provides the relatively quick and efficient treatment.
Acquired Hemophilia Market by Region
Based on regions, the market has been segmented into North America, Europe, Asia Pacific, and Rest of the World. North America dominates the global acquired hemophilia market with the largest revenue share and is also expected to retain its lead in the forecast period. The growth of this market can be owed to the large expenditure provided by the government and funding for research and development (R&D), and collaborations with prominent market players. The advancement in technological devices/treatment methods and rising targeted patient base impacts business revenue globally.
Some of the prominent players operating in the global acquired hemophilia treatment market are: